clinical trial · NCT06937086
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company·phase3·recruiting·n = 350
Ulcerative ColitisObesity or OverweightMirikizumabMirikizumabTirzepatidePlacebo
brief summary
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
started
Jun 26, 2025
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
May 12, 2026
official title
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol